Biomarker Study of Pancreatic Neuroendocrine Tumours

Status Recruiting

Clinical Trial Summary

The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor hormone secretion. This study aims to characterize how the biology of pancreatic neuroendocrine tumors change over time, measured by; patient symptoms, biochemistry, contrast enhanced computed tomography, DOTATOC-PET, FDG-PET and core needle biopsy with histopathological analysis (Ki67 index and tumor cell differentiation). Uptake on 68Ga-DOTATOC and 18F-FDG-PET will be correlated directly to tumor cell proliferation rate. Fraction of patients with spatial heterogeneity in DOTATOC as well as FDG uptake as well as metachronous changes in all collected data will be documented. Biomaterial from whole blood and core needle biopsies will be characterized on the molecular level, and those findings will be integrated to the above specified clinical parameters.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03741517
Study type	Observational [Patient Registry]
Source	Uppsala University
Contact	Joakim Crona, MD, PhD
Phone	0046186110000
Email	joakim.crona@medsci.uu.se
Status	Recruiting
Phase
Start date	January 30, 2019
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05566093` - EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors	N/A
Completed	`NCT00970970` - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease	N/A
Recruiting	`NCT05568017` - Neoadjuvant PRRT With Y-90-DOTATOC in pNET	Phase 2
Not yet recruiting	`NCT06024343` - Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction	N/A
Recruiting	`NCT03891784` - Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors	Phase 2
Recruiting	`NCT03204019` - A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor	Phase 2
Completed	`NCT00804336` - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors	Phase 1
Recruiting	`NCT05997056` - Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors	Phase 2
Not yet recruiting	`NCT06158516` - A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors	Phase 2
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma	Phase 1
Recruiting	`NCT05040360` - Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors	Phase 2
Recruiting	`NCT05988918` - Multicenter Trial of ESK981 in Patients With Select Solid Tumors	Phase 2
Completed	`NCT00576680` - RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors	Phase 1/Phase 2
Recruiting	`NCT05610826` - Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver	Phase 1/Phase 2
Active, not recruiting	`NCT03074513` - Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	Phase 2
Completed	`NCT03967951` - CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
Completed	`NCT01024387` - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Phase 2
Not yet recruiting	`NCT03435770` - Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms	N/A
Recruiting	`NCT04134832` - Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
Recruiting	`NCT05554744` - EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors	N/A